# A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Source: https://onco.cc/trials/nct06062420/  
OnCo record `nct06062420` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dostarlimab in head and neck squamous cell carcinoma, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 is a phase 2 interventional study registered as NCT06062420 by GlaxoSmithKline, with 316 participants enrolled, started 2023-11-14 and due to reach its primary completion in 2026-09-01. Interventions recorded: Dostarlimab, Belrestotug, Nelistotug and Remzistotug.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06062420
- Phase: 2
- Setting: A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
- Sponsor: GlaxoSmithKline
- Enrolled: 316

## Sources

- ClinicalTrials.gov NCT06062420: https://clinicaltrials.gov/study/NCT06062420

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06062420.json